{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,9]],"date-time":"2026-11-09T19:53:51Z","timestamp":1794254031290,"version":"4.9.0"},"reference-count":79,"publisher":"American Society of Hematology","issue":"22","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2011,11,24]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Autoimmune lymphoproliferative syndrome (ALPS) represents a failure of apoptotic mechanisms to maintain lymphocyte homeostasis, permitting accumulation of lymphoid mass and persistence of autoreactive cells that often manifest in childhood with chronic nonmalignant lymphadenopathy, hepatosplenomegaly, and recurring multilineage cytopenias. Cytopenias in these patients can be the result of splenic sequestration as well as autoimmune complications manifesting as autoimmune hemolytic anemia, immune-mediated thrombocytopenia, and autoimmune neutropenia. More than 300 families with hereditary ALPS have now been described; nearly 500 patients from these families have been studied and followed worldwide over the last 20 years by our colleagues and ourselves. Some of these patients with FAS mutations affecting the intracellular portion of the FAS protein also have an increased risk of B-cell lymphoma. The best approaches to diagnosis, follow-up, and management of ALPS, its associated cytopenias, and other complications resulting from infiltrative lymphoproliferation and autoimmunity are presented. This trial was registered at www.clinicaltrial.gov as #NCT00001350.<\/jats:p>","DOI":"10.1182\/blood-2011-07-325217","type":"journal-article","created":{"date-parts":[[2011,9,2]],"date-time":"2011-09-02T00:46:34Z","timestamp":1314924394000},"page":"5741-5751","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":166,"title":["How I treat autoimmune lymphoproliferative syndrome"],"prefix":"10.1182","volume":"118","author":[{"given":"V. Koneti","family":"Rao","sequence":"first","affiliation":[{"name":"ALPS Unit, Laboratory of Clinical and Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health (NIH), Bethesda, MD; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jo\u00e3o Bosco","family":"Oliveira","sequence":"additional","affiliation":[{"name":"Human Disorders of Lymphocyte Homeostasis Unit, Immunology Service, Department of Laboratory Medicine, Clinical Center, NIH, Bethesda, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"6","key":"2019111807562058900_B1","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1038\/82712","article-title":"The multifaceted role of Fas signaling in immune cell homeostasis and autoimmunity.","volume":"1","author":"Siegel","year":"2000","journal-title":"Nat Immunol"},{"issue":"15","key":"2019111807562058900_B2","doi-asserted-by":"crossref","first-page":"10709","DOI":"10.1016\/S0021-9258(19)50076-X","article-title":"Purification and molecular cloning of the APO-1 cell surface antigen, a member of the tumor necrosis factor\/nerve growth factor receptor superfamily: sequence identity with the Fas antigen.","volume":"267","author":"Oehm","year":"1992","journal-title":"J Biol Chem"},{"key":"2019111807562058900_B3","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1146\/annurev.iy.09.040191.001331","article-title":"Lpr and gld: single gene models of systemic autoimmunity and lymphoproliferative disease.","volume":"9","author":"Cohen","year":"1991","journal-title":"Annu Rev Immunol"},{"issue":"5475","key":"2019111807562058900_B4","doi-asserted-by":"crossref","first-page":"2354","DOI":"10.1126\/science.288.5475.2354","article-title":"Fas preassociation required for apoptosis signaling and dominant inhibition by pathogenic mutations.","volume":"288","author":"Siegel","year":"2000","journal-title":"Science"},{"issue":"1","key":"2019111807562058900_B5","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1006\/smim.1996.0055","article-title":"Portrait of an executioner: the molecular mechanism of FAS\/APO-1-induced apoptosis.","volume":"9","author":"Chinnaiyan","year":"1997","journal-title":"Semin Immunol"},{"issue":"3","key":"2019111807562058900_B6","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1084\/jem.183.3.721","article-title":"Fas and the art of lymphocyte maintenance.","volume":"183","author":"Lenardo","year":"1996","journal-title":"J Exp Med"},{"issue":"6367","key":"2019111807562058900_B7","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1038\/356314a0","article-title":"Lymphoproliferation disorder in mice explained by defects in Fas antigen that mediates apoptosis.","volume":"356","author":"Watanabe-Fukunaga","year":"1992","journal-title":"Nature"},{"issue":"24","key":"2019111807562058900_B8","doi-asserted-by":"crossref","first-page":"14175","DOI":"10.1073\/pnas.2336198100","article-title":"Shutdown of an acute T cell immune response to viral infection is mediated by the proapoptotic Bcl-2 homology 3-only protein Bim.","volume":"100","author":"Pellegrini","year":"2003","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"2","key":"2019111807562058900_B9","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.immuni.2007.12.017","article-title":"Apoptosis regulators Fas and Bim cooperate in shutdown of chronic immune responses and prevention of autoimmunity.","volume":"28","author":"Hughes","year":"2008","journal-title":"Immunity"},{"issue":"2","key":"2019111807562058900_B10","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1016\/j.immuni.2007.12.014","article-title":"Apoptosis regulators Bim and Fas function concurrently to control autoimmunity and CD8+ T cell contraction.","volume":"28","author":"Weant","year":"2008","journal-title":"Immunity"},{"issue":"2","key":"2019111807562058900_B11","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1172\/JCI115867","article-title":"A novel lymphoproliferative\/autoimmune syndrome resembling murine lpr\/gld disease.","volume":"90","author":"Sneller","year":"1992","journal-title":"J Clin Invest"},{"issue":"5215","key":"2019111807562058900_B12","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1126\/science.7539157","article-title":"Mutations in Fas associated with human lymphoproliferative syndrome and autoimmunity.","volume":"268","author":"Rieux-Laucat","year":"1995","journal-title":"Science"},{"issue":"6","key":"2019111807562058900_B13","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1016\/0092-8674(95)90013-6","article-title":"Dominant interfering Fas gene mutations impair apoptosis in a human autoimmune lymphoproliferative syndrome.","volume":"81","author":"Fisher","year":"1995","journal-title":"Cell"},{"issue":"4","key":"2019111807562058900_B14","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1182\/blood.V89.4.1341","article-title":"Clinical, immunologic, and genetic features of an autoimmune lymphoproliferative syndrome associated with abnormal lymphocyte apoptosis.","volume":"89","author":"Sneller","year":"1997","journal-title":"Blood"},{"issue":"4","key":"2019111807562058900_B15","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1097\/00002281-200307000-00008","article-title":"Autoimmune lymphoproliferative syndrome.","volume":"15","author":"Sneller","year":"2003","journal-title":"Curr Opin Rheumatol"},{"issue":"3","key":"2019111807562058900_B16","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1016\/j.ajo.2004.09.017","article-title":"Bilateral uveitis in a patient with autoimmune lymphoproliferative syndrome.","volume":"139","author":"Lim","year":"2005","journal-title":"Am J Ophthalmol"},{"issue":"4","key":"2019111807562058900_B17","doi-asserted-by":"crossref","first-page":"1384","DOI":"10.1053\/gast.1997.v113.pm9322534","article-title":"Fas\/Apo1 mutations and autoimmune lymphoproliferative syndrome in a patient with type 2 autoimmune hepatitis.","volume":"113","author":"Pensati","year":"1997","journal-title":"Gastroenterology"},{"issue":"5","key":"2019111807562058900_B18","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1007\/s00467-003-1087-3","article-title":"Autoimmune lymphoproliferative syndrome presenting with glomerulonephritis.","volume":"18","author":"Kanegane","year":"2003","journal-title":"Pediatr Nephrol"},{"issue":"6","key":"2019111807562058900_B19","first-page":"906","article-title":"Extra-nodal manifestations of ALPS and related disorders: infiltrative pulmonary lesions.","volume":"56","author":"Perkins","year":"2011","journal-title":"Pediatr Blood Cancer"},{"issue":"7","key":"2019111807562058900_B20","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1002\/ajh.20851","article-title":"Eosinophilia is associated with a higher mortality rate among patients with autoimmune lymphoproliferative syndrome.","volume":"82","author":"Kim","year":"2007","journal-title":"Am J Hematol"},{"issue":"1","key":"2019111807562058900_B21","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1046\/j.1537-2995.2001.41010018.x","article-title":"RBC autoantibodies in autoimmune lymphoproliferative syndrome.","volume":"41","author":"Stroncek","year":"2001","journal-title":"Transfusion"},{"issue":"4","key":"2019111807562058900_B22","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1111\/j.0042-9007.2003.00374.x","article-title":"Neutrophil and platelet antibodies in autoimmune lymphoproliferative syndrome.","volume":"85","author":"Kwon","year":"2003","journal-title":"Vox Sang"},{"issue":"3","key":"2019111807562058900_B23","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1002\/1096-8652(200007)64:3<214::AID-AJH14>3.0.CO;2-T","article-title":"Report of a factor VIII inhibitor in a patient with autoimmune lymphoproliferative syndrome.","volume":"64","author":"Fang","year":"2000","journal-title":"Am J Hematol"},{"issue":"14","key":"2019111807562058900_B24","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1056\/NEJMoa040036","article-title":"Autoimmune lymphoproliferative syndrome with somatic Fas mutations.","volume":"351","author":"Holzelova","year":"2004","journal-title":"N Engl J Med"},{"issue":"25","key":"2019111807562058900_B25","doi-asserted-by":"crossref","first-page":"5164","DOI":"10.1182\/blood-2010-01-263145","article-title":"Somatic FAS mutations are common in patients with genetically undefined autoimmune lymphoproliferative syndrome.","volume":"115","author":"Dowdell","year":"2010","journal-title":"Blood"},{"issue":"5","key":"2019111807562058900_B26","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1016\/S0022-3476(98)70102-7","article-title":"The clinical spectrum in a large kindred with autoimmune lymphoproliferative syndrome caused by a Fas mutation that impairs lymphocyte apoptosis.","volume":"133","author":"Infante","year":"1998","journal-title":"J Pediatr"},{"issue":"1","key":"2019111807562058900_B27","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1172\/JCI43752","article-title":"Onset of autoimmune lymphoproliferative syndrome (ALPS) in humans as a consequence of genetic defect accumulation.","volume":"121","author":"Magerus-Chatinet","year":"2011","journal-title":"J Clin Invest"},{"issue":"10","key":"2019111807562058900_B28","doi-asserted-by":"crossref","first-page":"6035","DOI":"10.4049\/jimmunol.1100021","article-title":"FAS haploinsufficiency is a common disease mechanism in the human autoimmune lymphoproliferative syndrome.","volume":"186","author":"Kuehn","year":"2011","journal-title":"J Immunol"},{"issue":"1","key":"2019111807562058900_B29","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1182\/blood.V98.1.194","article-title":"The development of lymphomas in families with autoimmune lymphoproliferative syndrome with germline Fas mutations and defective lymphocyte apoptosis.","volume":"98","author":"Straus","year":"2001","journal-title":"Blood"},{"key":"2019111807562058900_B30","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1186\/1471-2350-8-41","article-title":"Dominant inhibition of Fas ligand-mediated apoptosis due to a heterozygous mutation associated with autoimmune lymphoproliferative syndrome (ALPS) Type Ib.","volume":"8","author":"Bi","year":"2007","journal-title":"BMC Med Genet"},{"issue":"3","key":"2019111807562058900_B31","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1007\/s00439-006-0138-9","article-title":"Genetic alterations in caspase-10 may be causative or protective in autoimmune lymphoproliferative syndrome.","volume":"119","author":"Zhu","year":"2006","journal-title":"Hum Genet"},{"issue":"6","key":"2019111807562058900_B32","doi-asserted-by":"crossref","first-page":"2443","DOI":"10.1182\/blood-2004-09-3542","article-title":"Unmasking Evans syndrome: T-cell phenotype and apoptotic response reveal autoimmune lymphoproliferative syndrome (ALPS).","volume":"105","author":"Teachey","year":"2005","journal-title":"Blood"},{"issue":"7","key":"2019111807562058900_B33","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1097\/01.pas.0000157997.61177.08","article-title":"Histologic features of sinus histiocytosis with massive lymphadenopathy in patients with autoimmune lymphoproliferative syndrome.","volume":"29","author":"Maric","year":"2005","journal-title":"Am J Surg Pathol"},{"issue":"3","key":"2019111807562058900_B34","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1016\/j.clim.2010.08.008","article-title":"Clinical and immunological overlap between autoimmune lymphoproliferative syndrome and common variable immunodeficiency.","volume":"137","author":"Rensing-Ehl","year":"2010","journal-title":"Clin Immunol"},{"issue":"7","key":"2019111807562058900_B35","doi-asserted-by":"crossref","first-page":"591","DOI":"10.7326\/0003-4819-130-7-199904060-00020","article-title":"An inherited disorder of lymphocyte apoptosis: the autoimmune lymphoproliferative syndrome.","volume":"130","author":"Straus","year":"1999","journal-title":"Ann Intern Med"},{"issue":"14","key":"2019111807562058900_B36","doi-asserted-by":"crossref","first-page":"e35","DOI":"10.1182\/blood-2010-04-280347","article-title":"Revised diagnostic criteria and classification for the autoimmune lymphoproliferative syndrome (ALPS): report from the 2009 NIH International Workshop.","volume":"116","author":"Oliveira","year":"2010","journal-title":"Blood"},{"issue":"4","key":"2019111807562058900_B37","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1016\/j.jaci.2009.12.983","article-title":"Using biomarkers to predict the presence of FAS mutations in patients with features of the autoimmune lymphoproliferative syndrome.","volume":"125","author":"Caminha","year":"2010","journal-title":"J Allergy Clin Immunol"},{"issue":"6","key":"2019111807562058900_B38","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1136\/bjo.2009.171264","article-title":"Scleritis and multiple systemic autoimmune manifestations in chronic natural killer cell lymphocytosis associated with elevated TCRalpha\/beta+CD3+CD4\u2212CD8\u2212 double-negative T cells.","volume":"94","author":"Yeh","year":"2010","journal-title":"Br J Ophthalmol"},{"issue":"8","key":"2019111807562058900_B39","doi-asserted-by":"crossref","first-page":"4552","DOI":"10.1073\/pnas.96.8.4552","article-title":"Defective CD95\/APO-1\/Fas signal complex formation in the human autoimmune lymphoproliferative syndrome, type Ia.","volume":"96","author":"Martin","year":"1999","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"5","key":"2019111807562058900_B40","doi-asserted-by":"crossref","first-page":"501","DOI":"10.3109\/10428190109060341","article-title":"Autoimmune lymphoproliferative syndrome type III, an indefinite disorder.","volume":"41","author":"van der Werff ten Bosch","year":"2001","journal-title":"Leuk Lymphoma"},{"issue":"6905","key":"2019111807562058900_B41","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1038\/nature01063","article-title":"Pleiotropic defects in lymphocyte activation caused by caspase-8 mutations lead to human immunodeficiency.","volume":"419","author":"Chun","year":"2002","journal-title":"Nature"},{"issue":"21","key":"2019111807562058900_B42","doi-asserted-by":"crossref","first-page":"8953","DOI":"10.1073\/pnas.0702975104","article-title":"NRAS mutation causes a human autoimmune lymphoproliferative syndrome.","volume":"104","author":"Oliveira","year":"2007","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"10","key":"2019111807562058900_B43","doi-asserted-by":"crossref","first-page":"2883","DOI":"10.1182\/blood-2010-07-295501","article-title":"Somatic KRAS mutations associated with a human nonmalignant syndrome of autoimmunity and abnormal leukocyte homeostasis.","volume":"117","author":"Niemela","year":"2011","journal-title":"Blood"},{"issue":"10","key":"2019111807562058900_B44","doi-asserted-by":"crossref","first-page":"2887","DOI":"10.1182\/blood-2010-08-301515","article-title":"Autoimmune lymphoproliferative syndrome-like disease with somatic KRAS mutation.","volume":"117","author":"Takagi","year":"2011","journal-title":"Blood"},{"issue":"13","key":"2019111807562058900_B45","doi-asserted-by":"crossref","first-page":"3027","DOI":"10.1182\/blood-2008-09-179630","article-title":"FAS-L, IL-10, and double-negative CD4\u2212 CD8\u2212 TCR alpha\/beta+ T cells are reliable markers of autoimmune lymphoproliferative syndrome (ALPS) associated with FAS loss of function.","volume":"113","author":"Magerus-Chatinet","year":"2009","journal-title":"Blood"},{"issue":"5","key":"2019111807562058900_B46","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1016\/S0002-9440(10)65742-2","article-title":"Pathological findings in human autoimmune lymphoproliferative syndrome.","volume":"153","author":"Lim","year":"1998","journal-title":"Am J Pathol"},{"issue":"4","key":"2019111807562058900_B47","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1086\/302333","article-title":"Autoimmune lymphoproliferative syndrome with defective Fas: genotype influences penetrance.","volume":"64","author":"Jackson","year":"1999","journal-title":"Am J Hum Genet"},{"issue":"20","key":"2019111807562058900_B48","first-page":"5640","article-title":"Somatic mutations of the CD95 gene in Hodgkin and Reed-Sternberg cells.","volume":"60","author":"Muschen","year":"2000","journal-title":"Cancer Res"},{"issue":"12","key":"2019111807562058900_B49","doi-asserted-by":"crossref","first-page":"1833","DOI":"10.1084\/jem.192.12.1833","article-title":"Somatic mutation of the CD95 gene in human B cells as a side-effect of the germinal center reaction.","volume":"192","author":"Muschen","year":"2000","journal-title":"J Exp Med"},{"issue":"6","key":"2019111807562058900_B50","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1007\/s001090000112","article-title":"Defining CD95 as a tumor suppressor gene.","volume":"78","author":"Muschen","year":"2000","journal-title":"J Mol Med"},{"issue":"3","key":"2019111807562058900_B51","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1080\/10428190310001593166","article-title":"Development of lymphoma in autoimmune lymphoproliferative syndrome (ALPS) and its relationship to Fas gene mutations.","volume":"45","author":"Poppema","year":"2004","journal-title":"Leuk Lymphoma"},{"issue":"4","key":"2019111807562058900_B52","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1097\/PAS.0b013e3181d5ddf8","article-title":"Development of disseminated histiocytic sarcoma in a patient with autoimmune lymphoproliferative syndrome and associated Rosai-Dorfman disease.","volume":"34","author":"Venkataraman","year":"2010","journal-title":"Am J Surg Pathol"},{"issue":"1","key":"2019111807562058900_B53","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1148\/radiology.212.1.r99jl40257","article-title":"Autoimmune lymphoproliferative syndrome: a syndrome associated with inherited genetic defects that impair lymphocytic apoptosis\u2014CT and US features.","volume":"212","author":"Avila","year":"1999","journal-title":"Radiology"},{"issue":"2","key":"2019111807562058900_B54","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1002\/ajh.20523","article-title":"Fluorodeoxyglucose positron emission tomography (FDG-PET) for monitoring lymphadenopathy in the autoimmune lymphoproliferative syndrome (ALPS).","volume":"81","author":"Rao","year":"2006","journal-title":"Am J Hematol"},{"issue":"12","key":"2019111807562058900_B55","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1002\/ajh.21007","article-title":"Pyrimethamine treatment does not ameliorate lymphoproliferation or autoimmune disease in MRL\/lpr\u2212\/\u2212 mice or in patients with autoimmune lymphoproliferative syndrome.","volume":"82","author":"Rao","year":"2007","journal-title":"Am J Hematol"},{"issue":"2","key":"2019111807562058900_B56","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1182\/blood-2007-05-087353","article-title":"Targeting Notch signaling in autoimmune and lymphoproliferative disease.","volume":"111","author":"Teachey","year":"2008","journal-title":"Blood"},{"issue":"4","key":"2019111807562058900_B57","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1016\/j.exphem.2008.12.002","article-title":"Valproic acid (VPA), a histone deacetylase (HDAC) inhibitor, diminishes lymphoproliferation in the Fas-deficient MRL\/lpr(\u2212\/\u2212) murine model of autoimmune lymphoproliferative syndrome (ALPS).","volume":"37","author":"Dowdell","year":"2009","journal-title":"Exp Hematol"},{"issue":"13","key":"2019111807562058900_B58","doi-asserted-by":"crossref","first-page":"3967","DOI":"10.1182\/blood-2006-04-020610","article-title":"Arsenic trioxide: a promising novel therapeutic agent for lymphoproliferative and autoimmune syndromes in MRL\/lpr mice.","volume":"108","author":"Bobe","year":"2006","journal-title":"Blood"},{"issue":"2","key":"2019111807562058900_B59","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1002\/art.1780370219","article-title":"Rapamycin prolongs survival and arrests pathophysiologic changes in murine systemic lupus erythematosus.","volume":"37","author":"Warner","year":"1994","journal-title":"Arthritis Rheum"},{"issue":"6","key":"2019111807562058900_B60","doi-asserted-by":"crossref","first-page":"1965","DOI":"10.1182\/blood-2006-01-010124","article-title":"Rapamycin improves lymphoproliferative disease in murine autoimmune lymphoproliferative syndrome (ALPS).","volume":"108","author":"Teachey","year":"2006","journal-title":"Blood"},{"issue":"1","key":"2019111807562058900_B61","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1111\/j.1365-2141.2009.07595.x","article-title":"Treatment with sirolimus results in complete responses in patients with autoimmune lymphoproliferative syndrome.","volume":"145","author":"Teachey","year":"2009","journal-title":"Br J Haematol"},{"issue":"21","key":"2019111807562058900_B62","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.1182\/blood.V116.21.3908.3908","article-title":"Causes and consequences of splenectomy in ALPS-FAS.","volume":"116","author":"Price","year":"2010","journal-title":"Blood"},{"issue":"8","key":"2019111807562058900_B63","doi-asserted-by":"crossref","first-page":"2466","DOI":"10.1182\/blood.V98.8.2466","article-title":"Immunophenotypic profiles in families with autoimmune lymphoproliferative syndrome.","volume":"98","author":"Bleesing","year":"2001","journal-title":"Blood"},{"issue":"4","key":"2019111807562058900_B64","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1067\/S0022-3476(03)00331-7","article-title":"Invasive pneumococcal infections in children with sickle cell disease in the era of penicillin prophylaxis, antibiotic resistance, and 23-valent pneumococcal polysaccharide vaccination.","volume":"143","author":"Adamkiewicz","year":"2003","journal-title":"J Pediatr"},{"issue":"2","key":"2019111807562058900_B65","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1086\/345527","article-title":"Indications for the immunological evaluation of patients with meningitis.","volume":"36","author":"Overturf","year":"2003","journal-title":"Clin Infect Dis"},{"issue":"14","key":"2019111807562058900_B66","doi-asserted-by":"crossref","first-page":"2861","DOI":"10.1182\/blood-2009-04-210112","article-title":"Vascular complications after splenectomy for hematologic disorders.","volume":"114","author":"Crary","year":"2009","journal-title":"Blood"},{"issue":"8","key":"2019111807562058900_B67","doi-asserted-by":"crossref","first-page":"546","DOI":"10.7326\/0003-4819-151-8-200910200-00008","article-title":"Risk for hospital contact with infection in patients with splenectomy: a population-based cohort study.","volume":"151","author":"Thomsen","year":"2009","journal-title":"Ann Intern Med"},{"issue":"3","key":"2019111807562058900_B68","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/S0163-4453(97)93232-1","article-title":"A study of 42 episodes of overwhelming post-splenectomy infection: is current guidance for asplenic individuals being followed?","volume":"35","author":"Waghorn","year":"1997","journal-title":"J Infect"},{"issue":"1","key":"2019111807562058900_B69","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1080\/10245330500329094","article-title":"Causes and consequences of the autoimmune lymphoproliferative syndrome.","volume":"11","author":"Rao","year":"2006","journal-title":"Hematology"},{"issue":"16","key":"2019111807562058900_B70","doi-asserted-by":"crossref","first-page":"4190","DOI":"10.1182\/blood-2010-08-302984","article-title":"The American Society of Hematology 2011 evidence-based practice guideline for immune thrombocytopenia.","volume":"117","author":"Neunert","year":"2011","journal-title":"Blood"},{"issue":"7","key":"2019111807562058900_B71","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1002\/pbc.21965","article-title":"Use of rituximab for refractory cytopenias associated with autoimmune lymphoproliferative syndrome (ALPS).","volume":"52","author":"Rao","year":"2009","journal-title":"Pediatr Blood Cancer"},{"issue":"4","key":"2019111807562058900_B72","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1002\/pbc.21264","article-title":"Safety, efficacy, and immune reconstitution after rituximab therapy in pediatric patients with chronic or refractory hematologic autoimmune cytopenias.","volume":"50","author":"Rao","year":"2008","journal-title":"Pediatr Blood Cancer"},{"issue":"4","key":"2019111807562058900_B73","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1111\/j.1365-2141.2005.05496.x","article-title":"Use of mycophenolate mofetil for chronic, refractory immune cytopenias in children with autoimmune lymphoproliferative syndrome.","volume":"129","author":"Rao","year":"2005","journal-title":"Br J Haematol"},{"issue":"71","key":"2019111807562058900_B74","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1111\/j.1600-0609.2008.01208.x","article-title":"Immune thrombocytopenic purpura: the treatment paradigm.","author":"Stasi","year":"2009","journal-title":"Eur J Haematol Suppl"},{"issue":"1","key":"2019111807562058900_B75","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1002\/pbc.21729","article-title":"Response to mercaptopurine for refractory autoimmune cytopenias in children.","volume":"52","author":"Sobota","year":"2009","journal-title":"Pediatr Blood Cancer"},{"issue":"8","key":"2019111807562058900_B76","doi-asserted-by":"crossref","first-page":"2043","DOI":"10.1002\/eji.1830270831","article-title":"Correction of Fas (CD95) deficiency by haploidentical bone marrow transplantation.","volume":"27","author":"Benkerrou","year":"1997","journal-title":"Eur J Immunol"},{"issue":"4","key":"2019111807562058900_B77","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1038\/sj.bmt.1701306","article-title":"Correction of autoimmune lymphoproliferative syndrome by bone marrow transplantation.","volume":"22","author":"Sleight","year":"1998","journal-title":"Bone Marrow Transplant"},{"issue":"1","key":"2019111807562058900_B78","doi-asserted-by":"crossref","first-page":"e169","DOI":"10.1542\/peds.2009-1999","article-title":"Childhood polyarteritis nodosa in autoimmune lymphoproliferative syndrome.","volume":"125","author":"Naumann-Bartsch","year":"2010","journal-title":"Pediatrics"},{"key":"2019111807562058900_B79","article-title":"Autoimmune lymphoproliferative syndrome.","volume-title":"GeneReviews","author":"Bleesing","year":"1993"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/118\/22\/5741\/1345657\/zh804811005741.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/118\/22\/5741\/1345657\/zh804811005741.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,3]],"date-time":"2021-12-03T01:38:57Z","timestamp":1638495537000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/118\/22\/5741\/29181\/How-I-treat-autoimmune-lymphoproliferative"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,11,24]]},"references-count":79,"journal-issue":{"issue":"22","published-print":{"date-parts":[[2011,11,24]]}},"URL":"https:\/\/doi.org\/10.1182\/blood-2011-07-325217","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,11,24]]}}}